Alpha Tau Medical Ltd., a clinical-stage biopharmaceutical company, announced on May 7, 2026, that it will host a conference call to discuss interim results from the first three patients treated in its clinical trial for recurrent glioblastoma multiforme (GBM). The call is scheduled for May 12, 2026, at 8:30 a.m. ET.
The trial is evaluating Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a novel cancer treatment that uses alpha radiation to target tumors. According to the company's press release, the interim data from the first three patients showed promising safety and efficacy signals, with two patients achieving stable disease and one showing a partial response as of the data cutoff date of April 30, 2026.
Glioblastoma is an aggressive brain cancer with a poor prognosis, and recurrent GBM has limited treatment options. Alpha Tau's approach aims to deliver high-dose alpha radiation directly to the tumor site while sparing healthy tissue. The company plans to enroll up to 30 patients in this ongoing trial.
Investors and analysts will have the opportunity to ask questions during the conference call. The company emphasized that these are early-stage results and further data are needed to confirm the treatment's efficacy.
